PAVmed Inc. - PAVM STOCK NEWS

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) presented a meta-analysis on Remote Patient Monitoring (RPM) at the HIMSS23 Global Health Conference on April 19, 2023. This analysis, titled "RPM for Oncology: Bringing the Hospital Home to Improve Lives," highlights RPM's potential to enhance quality of care, reduce healthcare costs, and improve patient experiences. The meta-analysis reviewed nearly two decades of oncology research from over ten countries, emphasizing the integration of RPM with patient-reported outcomes (ePROs) for personalized cancer care. PAVmed's digital health subsidiary, Veris Health, showcased its Veris Cancer Care Platform™ during the session, which enables remote monitoring and real-time data transmission to improve patient management.

Lucid Diagnostics announced that Noridian Healthcare Solutions published a Future Effective Local Coverage Determination (LCD) DL39262, effective May 28, 2023. This LCD relates to molecular testing for esophageal precancer and cancer in Medicare beneficiaries. Lucid's EsoGuard Esophageal DNA Test is the only test in its category and aims to serve as a screening tool for at-risk patients. The LCD aligns with criteria from the Palmetto GBA MAC's MolDX Program. Lucid plans to secure clinical utility data and submit EsoGuard for Technical Assessment under these LCDs later this year, potentially expanding its testing access.

The company's CEO, Lishan Aklog, emphasized the milestone for increasing EsoGuard's accessibility to Medicare beneficiaries.

Lucid Diagnostics Inc. (NASDAQ: LUCD), a cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM, PAVMZ), announced its participation in the 22nd Annual Needham Healthcare Conference. Executives Dr. Lishan Aklog and Dennis McGrath will present on April 20, 2023, at 11:00 AM ET. Lucid focuses on patients with gastroesophageal reflux disease (GERD), a condition that increases the risk of esophageal precancer and cancer. Their flagship product, the EsoGuard® Esophageal DNA Test, is a non-invasive tool designed for early cancer detection in at-risk patients. For those interested in meeting with management during the conference, inquiries can be directed to Needham representatives. For more details, visit luciddx.com.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that its leadership team, including Dr. Lishan Aklog and Dennis McGrath, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 11:00 AM ET.

Lucid's focus is on patients with gastroesophageal reflux disease (GERD), at risk of esophageal cancer. Their EsoGuard® Esophageal DNA Test, a non-invasive diagnostic tool, is designed for early detection of esophageal precancer. This test is significant as it is the first commercially available screening tool targeting at-risk GERD patients.

For more details, visit luciddx.com or pavmed.com.

Lucid Diagnostics Inc. announced the publication of a Future Effective Local Coverage Determination (LCD) by the MolDX Program, effective May 14, 2023. This foundational LCD establishes coverage criteria for molecular testing of esophageal precancer and cancer for Medicare beneficiaries. Lucid plans to submit its EsoGuard Esophageal DNA Test for Technical Assessment under this LCD by the end of 2023, aiming to provide non-invasive testing alternatives to traditional endoscopy. The LCD incorporates feedback from stakeholders and aligns with the American College of Gastroenterology's guidelines, emphasizing early detection to prevent esophageal cancer deaths.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announced a business update and financial results for the year ended December 31, 2022. The company's restructuring plan has extended its cash runway, securing $24.6 million financing for Lucid Diagnostics, which is expected to last into 2024. Veris Health launched its Cancer Care Platform, enhancing patient monitoring. EsoGuard testing volume is growing, with recent agreements increasing access to up to 60 million consumers through MultiPlan. However, 2022 revenues were just $0.4 million, with a net loss of $89.2 million.

Lucid Diagnostics (NASDAQ: LUCD) reported significant growth in EsoGuard® test volumes, with 4Q22 showing an 8% sequential increase and a remarkable 288% year-over-year rise. The company anticipates 1Q23 to reflect approximately 1,600 tests, marking a 36% sequential and 300% annual growth. A strategic in-network agreement with MultiPlan broadens access to EsoGuard for 60 million consumers. Additionally, Lucid secured $24.6 million in financing through preferred stock and debt offerings, enhancing its cash runway into 2024 while focusing on commercial execution. Despite these positives, revenues remain low, with 4Q22 revenues at $0.1 million, and a net loss of $14.9 million reported.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announces a business update conference call scheduled for March 15, 2023, at 8:30 AM EST. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's growth strategy and report on the fourth-quarter 2022 financial results. Investors can access the webcast on the company's investor relations website or join via telephone with specific dial-in information provided. PAVmed operates in medical technology, with its subsidiaries, Lucid Diagnostics (NASDAQ: LUCD) and Veris Health, focusing on innovative cancer diagnostics and personalized cancer care, respectively.